A retrospective study assessing the incidence rate and risk factors for immune-related adverse events from Anti-PD-1/PD-L1 treatment in an Asian Patients with Non-small Cell Lung Cancer
Latest Information Update: 08 Mar 2022
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 15 Feb 2022 Results published in the International Journal of Cancer
- 09 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer